Diazyme launches beta-hydroxybutyrate assay

Create PDF

July 2021—Diazyme launched its FDA 510(k)–exempt Beta-Hydroxybutyrate Assay for the quantitative determination of beta-hydroxybutyrate. BHB serves as a guide for monitoring the progress of insulin therapy for diabetic ketoacid­osis and for patients presenting to the emergency room with documented hypoglycemia, acidosis, alcohol ingestion, or an unexplained increase in the anion gap.

The enzymatic BHB assay is a dual-vial, liquid-stable reagent designed for use on clinical chemistry analyzers. The assay uses a 2-μL sample volume of human serum or plasma and has a limit of detection of .006 mmol/L. Reagent stability is four weeks when stored at 2°–8°C.